Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results

Byrne, R. A.; Kufner, S.; Tiroch, K.; Massberg, S.; Laugwitz, K.-L.; Birkmeier, A.; Schulz, S.; Mehilli, J.
September 2009
Heart;Sep2009, Vol. 95 Issue 18, p11
Academic Journal
Background: Drug-eluting stent (DES) platforms devoid of durable polymer have potential to enhance long-term safety outcomes. The ISAR-TEST-3 study was a randomised trial comparing three rapamycin-eluting stents with different coating strategies. The present study examined 2-year outcomes of these patients and is the first large-scale trial to report longer-term outcomes with biodegradable polymer and polymer-free DES. Methods: Patients with de novo coronary lesions in native vessels were randomly assigned to receive biodegradable polymer (BP; n = 202), permanent polymer (PP; Cypher; n = 202) and polymer-free (PF; n = 201) stents. The 2-year endpoints of interest were target lesion revascularisation (TLR), death/myocardial infarction (MI), stent thrombosis and delayed angiographic late luminal loss (LLL) between 6-8 months and 2 years. Results: There were no significant differences in TLR (8.4%, 10.4% and 13.4% for BP, PP and PF stents, respectively; p = 0.19), death/MI (5.9%, 6.4% and 6.5% with BP, PP and PF respectively; p = 0.97) or stent thrombosis (definite/probable 0.5%, 1.0% and 1.0% with BP, PP and PF, respectively; p = 0.82). Paired angiographic follow-up at 6-8 months and 2 years was available for 302 patients (69.0% of eligible patients). Delayed LLL was significantly different across the treatment groups: 0.17 (0.42) mm, 0.16 (0.41) mm and -0.01 (0.36) mm for BP, PP and PF stents, respectively (p<0.001). Conclusion: Clinical antirestenotic efficacy was maintained with all three platforms between 1 and 2 years, although angiographic surveillance showed ongoing delayed LLL with both BP and PP stent platforms. At 2 years there was no signal of a differential safety profile between the three stent platforms.


Related Articles

  • Sirolimus.  // Reactions Weekly;8/11/2007, Issue 1164, p21 

    The article describes the cases of two elderly men who developed late stent restenosis of sirolimus-eluting stents. It references a study by T. Katayama and colleagues published in the June 2007 issue of the "Journal of Cardiology." The first patient underwent implantation of a sirolimus-eluting...

  • Systemic Immunosuppressive Therapy with Oral Sirolimus after Bare Metal Stent Implantation: The Missing Alternative in the Prevention of Coronary Restenosis after Percutaneous Coronary Interventions. Rodriguez, Alfredo E.; Fernandez-Pereira, Carlos // Recent Patents on Cardiovascular Drug Discovery;Nov2008, Vol. 3 Issue 3, p201 

    In recent years, percutaneous coronary intervention (PCI) with drug eluting stents (DES) to treat de novo coronary lesions has been associated with a significant reduction of neointimal hyperplasia and in-stent restenosis. However, several publications raise concerns about long-term safety of...

  • Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial). Rodríguez, A. E.; Alemparte, M. Rodríguez; Vigo, C. F.; Pereira, C. Fernández; Llauradó, C.; Vetcher, D.; Pocovi, A.; Ambrose, J. // Heart;Nov2005, Vol. 91 Issue 11, p1433 

    Objective: To assess the role of oral rapamycin in the prevention of coronary restenosis in patients undergoing coronary stenting. Methods: From December 2001 through February 2003, 76 patients with 103 de novo lesions treated percutaneously with bare stents received a loading dose of oral...

  • Sirolimus.  // Reactions Weekly;9/1/2012, Issue 1417, p42 

    The article describes the case of a 64-year-old man who developed in-stent restenosis (ISR) as a result of a hypersensitivity reaction after implantation of sirolimus-eluting stents.

  • Clinical Studies with Sirolimus, Zotarolimus, Everolimus and Biolimus A9 Drug-Eluting Stent Systems. Claessen, Bimmer E.; Henriques, José P. S.; Dangas, George D. // Current Pharmaceutical Design;12/11/2010, Vol. 16 Issue 36, p4012 

    No abstract available.

  • In vivo evaluation of a novel dexamethasone-heparin-double-coated stent for inhibition of artery restenosis and thrombosis. Qing-Kui Guo; Zhi-Qian Lu; Jin-Ye Wang; Tao Li // Journal of Materials Science: Materials in Medicine;Jun2011, Vol. 22 Issue 6, p1615 

    To evaluate the efficacy and safety of dexamethasone-heparin-double-coated stent (DHDCS) on inhibition of artery lumen reduction and neointimal hyperplasia in porcine model we carried out this study. Bare mental stents (BMS, n = 12), protein-coated stents (PCS, n = 12), heparin...

  • Biocompatibility of Coronary Stents. Jeewandara, Thamarasee M.; Wise, Steven G.; Ng, Martin K. C. // Materials (1996-1944);Feb2014, Vol. 7 Issue 2, p769 

    Cardiovascular disease is the dominant cause of mortality in developed countries, with coronary artery disease (CAD) a predominant contributor. The development of stents to treat CAD was a significant innovation, facilitating effective percutaneous coronary revascularization. Coronary stents...

  • In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function. Barilli, Amelia; Visigalli, Rossana; Sala, Roberto; Gazzola, Gian C.; Parolari, Alessandro; Tremoli, Elena; Bonomini, Sabrina; Simon, Alexandra; Closs, Ellen I.; Dall'Asta, Valeria; Bussolati, Ovidio // Cardiovascular Research;Jun2008, Vol. 78 Issue 3, p563 

    Aim: Drug-eluting stents are widely used to prevent restenosis but are associated with late endothelial damage. To understand the basis for this effect, we have studied the consequences of a prolonged incubation with rapamycin on the viability and functions of endothelial cells.

  • Sirolimus-eluting stent reduced risk for restenosis.  // Endocrine Today;4/10/2008, Vol. 6 Issue 6, p24 

    The article reports that researchers from Italy found out that sirolimus-eluting stents decrease the risk for restenosis. The study involves 60 patients assigned to sirolimus-eluting stent and 60 patients to paclitaxel-eluting stent. It shows that patients had lower in-stent luminal loss and the...


Read the Article


Sign out of this library

Other Topics